| Proteasome activation as a new therapeutic approach to target proteotoxic disorders E Njomen, JJ Tepe Journal of medicinal chemistry 62 (14), 6469-6481, 2019 | 96 | 2019 |
| Small molecule enhancement of 20S proteasome activity targets intrinsically disordered proteins CL Jones, E Njomen, B Sjögren, TS Dexheimer, JJ Tepe ACS chemical biology 12 (9), 2240-2247, 2017 | 87 | 2017 |
| Small molecule modulation of proteasome assembly E Njomen, PA Osmulski, CL Jones, M Gaczynska, JJ Tepe Biochemistry 57 (28), 4214-4224, 2018 | 64 | 2018 |
| Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain HC Feldman, E Merlini, C Guijas, KE DeMeester, E Njomen, EM Kozina, ... Proceedings of the National Academy of Sciences 119 (35), e2208457119, 2022 | 44 | 2022 |
| Proteomic discovery of chemical probes that perturb protein complexes in human cells MR Lazear, JR Remsberg, MG Jaeger, K Rothamel, H Her, KE DeMeester, ... Molecular cell 83 (10), 1725-1742. e12, 2023 | 38 | 2023 |
| Regulation of autophagic flux by the 20S proteasome E Njomen, JJ Tepe Cell chemical biology 26 (9), 1283-1294. e5, 2019 | 34 | 2019 |
| Humanin peptide binds to insulin-like growth factor-binding protein 3 (IGFBP3) and regulates its interaction with importin-β E Njomen, H G Evans, S H Gedara, D L Heyl Protein and Peptide Letters 22 (10), 869-876, 2015 | 30 | 2015 |
| Assigning functionality to cysteines by base editing of cancer dependency genes H Li, T Ma, JR Remsberg, SJ Won, KE DeMeester, E Njomen, ... Nature chemical biology 19 (11), 1320-1330, 2023 | 17 | 2023 |
| Chemical Proteomic Discovery of Isotype‐Selective Covalent Inhibitors of the RNA Methyltransferase NSUN2 Y Tao, JG Felber, Z Zou, E Njomen, JR Remsberg, D Ogasawara, C Ye, ... Angewandte Chemie International Edition 62 (51), e202311924, 2023 | 8 | 2023 |
| Comprehensive Mapping of Electrophilic Small Molecule-Protein Interactions in Human Cells B Cravatt, E Njomen, R Hayward, K DeMeester, D Ogasawara, M Dix, ... | 8 | 2023 |
| Small molecule 20S proteasome enhancer regulates MYC protein stability and exhibits antitumor activity in multiple myeloma E Njomen, A Vanecek, TA Lansdell, YT Yang, PZ Schall, CM Harris, ... Biomedicines 10 (5), 938, 2022 | 6 | 2022 |
| ACS Chem CL Jones, E Njomen, B Sjögren, TS Dexheimer, JJ Tepe Biol 12, 2240-2247, 2017 | 5 | 2017 |
| Proteomic Ligandability Maps of Spirocycle Acrylamide Stereoprobes Identify Covalent ERCC3 Degraders Z Liu, JR Remsberg, H Li, E Njomen, KE DeMeester, Y Tao, G Xia, ... Journal of the American Chemical Society 146 (15), 10393-10406, 2024 | 3 | 2024 |
| Covalent targeting as a common mechanism for inhibiting NLRP3 inflammasome assembly C Stanton, J Sun, K Nutsch, JD Rosarda, T Nguyen, C Li-Ma, E Njomen, ... ACS chemical biology 19 (2), 254-265, 2024 | 3 | 2024 |
| Redirecting the pioneering function of FOXA1 with covalent small molecules SJ Won, Y Zhang, CJ Reinhardt, NS MacRae, KE DeMeester, E Njomen, ... bioRxiv, 2024.03. 21.586158, 2024 | 3 | 2024 |
| Development of a cell-based alphaLISA assay for high-throughput screening for small molecule proteasome modulators SD Staerz, EM Lisabeth, E Njomen, TS Dexheimer, RR Neubig, JJ Tepe ACS omega 8 (17), 15650-15659, 2023 | 3 | 2023 |
| Chemical tools to expand the ligandable proteome: diversity-oriented synthesis-based photoreactive stereoprobes D Ogasawara, D Konrad, ZY Tan, K Carey, J Luo, SJ Won, H Li, T Carter, ... bioRxiv, 2024.02. 27.582206, 2024 | 2 | 2024 |
| Blocking oligomerization is the most viable strategy to inhibit STING R Chan, X Cao, SL Ergun, E Njomen, SR Lynch, BF Cravatt, L Li bioRxiv, 553045, 2023 | 2 | 2023 |
| Enhancing c-MYC degradation via 20S proteasome activation induces in vivo anti-tumor efficacy E Njomen, TA Lansdell, A Vanecek, V Benham, MP Bernard, YT Yang, ... bioRxiv, 2020.08. 24.265470, 2020 | 2 | 2020 |
| Cysteine allostery and autoinhibition govern human STING oligomer functionality L Li, R Chan, X Cao, S Ergun, E Njomen, S Lynch, C Ritchie, B Cravatt | | 2024 |
